CELC REVTORPYK sNDA: PIK3CA-Mutant Breast Cancer

Celcuity (NASDAQ: CELC) filed a supplemental New Drug Application (sNDA) on August 26 asking the FDA to expand REVTORPYK (gedatolisib) into HR+/HER2- advanced breast cancer with a PIK3CA mutation. Approval would extend the drug from the PIK3CA wild-type label it won on July 14 to nearly every HR+/HER2- patient, because about 40% of that subtype carries a PIK3CA mutation. The stock closed at $92.27.

The filing rests on the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial, which randomized 350 patients. Gedatolisib plus fulvestrant and palbociclib, the triplet, cut the risk of progression or death by 50% versus Novartis’ alpelisib (Piqray) plus fulvestrant, with a hazard ratio of 0.50 (p<0.0001) and median progression-free survival of 11.1 months versus 5.6 months. The doublet, gedatolisib plus fulvestrant, produced a hazard ratio of 0.51 and median PFS of 11.3 months. Objective response rates were 49% for the triplet and 36% for the doublet, with median response durations of 15.7 and 24.2 months.

This is a head-to-head win over the incumbent. Alpelisib has led the PIK3CA-mutant segment since 2019, and VIKTORIA-1 is the first trial to beat it directly. REVTORPYK blocks all four class I PI3K isoforms plus mTORC1 and mTORC2, a broader hit than alpelisib’s PI3K-alpha-only action. The tradeoff is the known PI3K-class safety burden: stomatitis, rash, and hyperglycemia stay on the label, with stomatitis in 72% of triplet patients.

Beyond the label expansion, Celcuity is already running VIKTORIA-2, a pair of first-line trials testing gedatolisib with palbociclib plus either fulvestrant or letrozole in treatment-naive patients, and a Phase 1/2 prostate cancer study combining the drug with darolutamide. The sNDA is the first step in a plan to make gedatolisib available across the full HR+/HER2- setting, not just the second-line niche.

The investor context is that Celcuity is six weeks past its first approval and already filing to roughly double its addressable market, yet the market has not rewarded the science. REVTORPYK won its wild-type approval July 14 and the stock sold off afterward, a move covered in this REVTORPYK analysis, and the NCCN’s 16-day Category 1 listing did not reverse it as detailed in the NCCN adoption coverage. The worry is a valuation built on a flawless launch with no revenue yet.

What to watch: the FDA has not set a PDUFA date, and Celcuity has not said whether it will seek priority review. The wild-type launch is on track for late Q3 2026. A six-month priority review would put a decision in early 2027. Here is how an sNDA works.

What It Means for the Trade

The VIKTORIA-1 mutant-cohort data is one of the cleanest head-to-head wins in recent breast cancer history — a 50% risk reduction (HR 0.50, p<0.0001) and a doubling of median PFS (11.1 versus 5.6 months) against the incumbent alpelisib in the same class — and the sNDA converts it into a dated regulatory path toward a market that roughly doubles the label. The commercial logic is straightforward: about 40% of HR+/HER2- patients carry PIK3CA mutations, and right now those patients are channeled to Piqray, a drug with a real tolerability reputation that has constrained its uptake since 2019. A triplet that beats Piqray directly with a manageable (if heavy — 72% stomatitis) safety profile gives oncologists a reason to test and treat the mutant population differently.

The puzzle the market keeps presenting is the stock’s refusal to reward the science — approval on July 14, NCCN Category 1 listing in 16 days, and now an sNDA filing, all without a sustained re-rate. The likely explanation is a valuation conversation the science can’t win: CELC at $92 is priced for a launch with no revenue yet, and the market is discounting execution risk — commercial buildout, reimbursement speed, and whether a small company can convert class-leading data into class-leading share against Novartis’s entrenched relationships. That discount either closes with launch metrics or it is correct.

Mechanism and Competitive Context

The mechanism argument is why the head-to-head win is credible rather than a trial-design artifact. Gedatolisib blocks all four class I PI3K isoforms plus mTORC1/2 — a broader footprint than alpelisib’s alpha-only inhibition — and the PI3K pathway’s redundancy is precisely why single-isoform blockade underdelivers clinically: tumors route around alpha blockade through beta and delta isoforms, and the mTORC arms sit downstream of every bypass. The cost of breadth is the class’s toxicity burden, and stomatitis at 72% on the triplet is the number payers and prescribers will study. The doublet arm (HR 0.51, median PFS 11.3 months) is the interesting commercial wrinkle — comparable efficacy to the triplet with presumably less toxicity stack, and the eventual label language on which regimen goes where will shape prescriber behavior more than the topline.

The strategic architecture matters for the model: VIKTORIA-2 is already running first-line combinations (with palbociclib plus fulvestrant or letrozole in treatment-naive patients), and a prostate cancer study pairs gedatolisib with darolutamide. If the mutant label lands and first-line data follows, gedatolisib’s endgame is the whole HR+/HER2- setting plus adjacent indications — a franchise thesis, not a niche one.

Risks and What Could Go Wrong

1. The FDA reads the open-label or design elements of VIKTORIA-1 differently than the market did — even a delay or an information request on a head-to-head win reopens the timing question the stock is not positioned for.
2. Launch execution: the wild-type launch’s first two quarters of revenue will either validate or destroy the premium valuation long before the mutant sNDA resolves.
3. Piqray’s entrenched incumbency: biomarker-tested patients already flow to alpelisib via habit and payer policy; switching requires detailing muscle Celcuity is still building.
4. Safety gradient: if real-world triplet tolerability drives dose interruptions the way Piqray’s did, the label breadth won’t matter — patients who can’t stay on the drug don’t stay on it.

Position read: CELC is a data-rich, execution-unproven story where the next two quarters of launch metrics matter more than another clinical win. The sNDA is thesis-confirming; the revenue line is thesis-deciding.

Source: Celcuity press release, August 26, 2026